We tested OM2BFB in two separate patient data sets: the first dataset was a cohort of 6 samples, including primary tumour and patient-derived xenografts from individuals who had HER2(+) breast cancer with brain metastases (BCBM)36,37. Here, ERBB2 is linked to breast cancer.